Now showing items 1-10 of 17
High and far: biases in the location of protected areas.
(PLoS One, 2009-12-14)
BACKGROUND: About an eighth of the earth's land surface is in protected areas (hereafter "PAs"), most created during the 20(th) century. Natural landscapes are critical for species persistence and PAs can play a major role ...
Are mature smokers misinformed?
(J Health Econ, 2009-03)
While there are many reasons to continue to smoke in spite of its consequences for health, the concern that many smoke because they misperceive the risks of smoking remains a focus of public discussion and motivates tobacco ...
Health events and the smoking cessation of middle aged Americans.
(J Behav Med, 2005-02)
This study investigates the effect of serious health events including new diagnoses of heart attacks, strokes, cancers, chronic lung disease, chronic heart failure, diabetes, and heart disease on future smoking status up ...
The effect of involuntary job loss on smoking intensity and relapse.
AIMS: To assess the impact of involuntary job loss due to plant closure or layoff on relapse to smoking and smoking intensity among older workers. DESIGN, PARTICIPANTS, SAMPLE: Data come from the Health and Retirement Study, ...
If smoking increases absences, does quitting reduce them?
(Tob Control, 2005-04)
OBJECTIVE: This study examined the impact of smoking, quitting, and time since quit on absences from work. METHODS: Data from the nationally representative Tobacco Use Supplements of the 1992/93, 1995/96, and 1998/99 Current ...
Should the patent system for new medicines be abolished?
(Clin Pharmacol Ther, 2007-11)
Burning a hole in the budget: tobacco spending and its crowd-out of other goods.
(Appl Health Econ Health Policy, 2004)
Smoking is an expensive habit. Smoking households spend, on average, more than $US1000 annually on cigarettes. When a family member quits, in addition to the former smoker's improved long-term health, families benefit because ...
The distribution of sales revenues from pharmaceutical innovation.
OBJECTIVE: This report updates our earlier work on the returns to pharmaceutical research and development (R&D) in the US (1980 to 1984), which showed that the returns distributions are highly skewed. It evaluates a more ...
The price of innovation: new estimates of drug development costs.
(J Health Econ, 2003-03)
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...
Economic return of clinical trials performed under the pediatric exclusivity program.
CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric ...